Document is current
Any future updates will be listed below
-
Authors
Puerta, Marta
Jaldo, María Teresa
Muñoz, Patricia
Martínez-Miguel, Patricia
Maduell, Francisco https://orcid.org/0000-0002-1673-0353
Lancho, Carolina
García-Herrera, Antonio Luis
Eloot, Sunny https://orcid.org/0000-0002-6984-1743
de Sequera, Patricia https://orcid.org/0000-0001-7705-9228
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct06505616 at ClinicalTrials.govDocuments that mention this clinical trial
SOLFA study: a multicenter, open-label, prospective, randomized study to investigate the clotting propensity of asymmetric cellulose triacetate membrane compared to synthetic membranes in on line HDF
https://doi.org/10.1007/s40620-024-02197-y
-
Funding
Funding for this research was provided by:
Nipro
- License Information
-
More Information
Article History
Received: 23 July 2024
Accepted: 15 December 2024
First Online: 19 January 2025
Declarations
:
: P.S. reports honorarium for conferences, consulting fees and advisory boards from Amgen, Astellas, Astra Zeneca, Baxter, Braun, Fresenius, Nipro, Vifor-Pharma. P.M. reports honorarium for conferences and consulting fee from Nipro. F.M. has received consultancy and lecture fees from Baxter, Fresenius Medical Care, Medtronic, Nipro, Toray, and Vifor. The remaining authors declare no potential conflicts of interest related to the contents of this article.
: The study was approved by the local Ethics Committee, and it was conducted according to the principles of the Declaration of Helsinki.
: All patients who participated in the study provided signed informed consent.
